首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.
【24h】

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

机译:药物诱导CYP3A4的作用:妊娠X受体报道基因基因测定与人肝细胞中CYP3A4表达之间的相关性。

获取原文
获取原文并翻译 | 示例
           

摘要

Induction of cytochrome P450 3A4 (CYP3A4) is determined typically by employing primary culture of human hepatocytes and measuring CYP3A4 mRNA, protein and microsomal activity. Recently a pregnane X receptor (PXR) reporter gene assay was established to screen CYP3A4 inducers. To evaluate results from the PXR reporter gene assay with those from the aforementioned conventional assays, 14 drugs were evaluated for their ability to induce CYP3A4 and activate PXR. Sandwiched primary cultures of human hepatocytes from six donors were used and CYP3A4 activity was assessed by measuring microsomal testosterone 6beta-hydroxylase activity. Hepatic CYP3A4 mRNA and protein levels were also analyzed using branched DNA technology/Northern blotting and Western blotting, respectively. In general, PXR activation correlated with the induction potential observed in human hepatocyte cultures. Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system. Ritonavir and troleandomycin showed marked PXR activation but no increase (in the case of troleandomycin) or a significant decrease (in the case of ritonavir) in microsomal CYP3A4 activity. It is concluded that the PXR reporter gene assay is a reliable and complementary method to assess the CYP3A4 induction potential of drugs and other xenobiotics.
机译:通常通过采用人肝细胞的原代培养并测量CYP3A4 mRNA,蛋白质和微粒体活性来确定细胞色素P450 3A4(CYP3A4)的诱导。最近建立了孕烷X受体(PXR)报告基因试验,以筛选CYP3A4诱导剂。为了评估PXR报告基因试验与上述常规试验的结果,评估了14种药物诱导CYP3A4和激活PXR的能力。使用来自六个供体的人肝细胞的夹层原代培养物,并通过测量微粒体睾丸激素6β-羟化酶活性来评估CYP3A4活性。还分别使用分支DNA技术/ Northern印迹和Western印迹分析了肝CYP3A4 mRNA和蛋白水平。通常,PXR激活与人类肝细胞培养物中观察到的诱导潜力相关。克霉唑,苯巴比妥,利福平和亚砜吡嗪高度活化PXR并增加CYP3A4活性;卡马西平,地塞米松,地塞米松-乙酸叔丁酯,苯妥英钠,磺胺二甲嘧啶和紫杉醇弱激活PXR并诱导CYP3A4活性,而甲氨蝶呤和丙磺舒在这两个系统中均未显示明显激活。 Ritonavir和troleandomycin显示明显的PXR活化作用,但微粒体CYP3A4活性没有增加(在troleandomycin的情况下)或没有明显的减少(在ritonavir情况下)。结论是,PXR报告基因测定是评估药物和其他异源物质对CYP3A4诱导潜力的可靠且互补的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号